Papaverine hydrochloride solution 2%, No. 10

Spasms of smooth muscles of the abdominal organs, bronchi, peripheral vessels, cerebral vessels, kidneys; angina pectoris (as part of combination therapy).

As an aid for sedation.

When administered intramuscularly, subcutaneously or intravenously, a single dose for adults is 10-20 mg; the interval between injections is at least 4 hours. For elderly patients, the initial single dose is not more than 10 mg. For children aged 1 to 12 years, the maximum single dose is 200-300 mcg / kg.

solution for injection 2%

papaverine hydrochloride

AV blockade, glaucoma, severe liver failure, old age (risk of hyperthermia), children under 6 months of age, hypersensitivity to papaverine.

pharmachologic effect

Myotropic antispasmodic. Inhibits PDE, causes the accumulation of cAMP in the cell and reduces the content of intracellular calcium. Reduces the tone of smooth muscles of internal organs (gastrointestinal tract, respiratory, urinary, reproductive system) and blood vessels. It causes the expansion of the arteries, increases blood flow, incl. cerebral. Has a hypotensive effect.

In high doses, it reduces the excitability of the heart muscle and slows down intracardiac conduction.

When used in moderate therapeutic doses, the effect on the central nervous system is weak.

Pharmacokinetics

Bioavailability is 54%. Plasma protein binding - 90%. It is well distributed in the body, penetrates the histohematogenous barriers. It is metabolized in the liver.

T1 / 2 - 0.5-2 hours. Increase up to 24 hours is possible.

It is excreted by the kidneys in the form of metabolites. It is completely removed from the blood during dialysis.

Indications of the active substances of the drug Papaverine

Spasms of smooth muscles of the abdominal organs, bronchi, peripheral vessels, cerebral vessels, kidneys; angina pectoris (as part of combination therapy).

As an aid for sedation.

Side effect

Possibly: nausea, constipation, drowsiness, excessive sweating, arterial hypotension, increased activity of hepatic transaminases.

With a rapid on / in the introduction, as well as when used in high doses: the development of AV blockade, cardiac arrhythmias.

Contraindications for use

AV blockade, glaucoma, severe liver failure, old age (risk of hyperthermia), children under 6 months of age, hypersensitivity to papaverine.

Application during pregnancy and lactation

During pregnancy and lactation (breastfeeding), the safety and efficacy of papaverine has not been established.

Application for violations of liver function

Contraindicated in severe hepatic impairment.

Application in children

Contraindicated in children under 6 months of age.

Use in elderly patients

Contraindicated in old age (risk of developing hyperthermia).

special instructions

Use with caution in conditions after traumatic brain injury, chronic renal failure, adrenal insufficiency, hypothyroidism, prostatic hyperplasia, supraventricular tachycardia, shock conditions.

IV should be administered slowly and under medical supervision.

During the period of treatment, alcohol consumption should be excluded.

Drug interactions

With simultaneous use with anticholinergics, anticholinergic effects may be enhanced.

It is believed that when used simultaneously with alprostadil for intracavernous administration, there is a risk of developing priapism.

There are reports of a decrease in the effectiveness of levodopa with its simultaneous use.

Reduces the hypotensive effect of methyldopa.